ECSP961693A - ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINE - Google Patents
ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINEInfo
- Publication number
- ECSP961693A ECSP961693A ECSP961693A ECSP961693A EC SP961693 A ECSP961693 A EC SP961693A EC SP961693 A ECSP961693 A EC SP961693A EC SP961693 A ECSP961693 A EC SP961693A
- Authority
- EC
- Ecuador
- Prior art keywords
- oral formulation
- cellulose
- hypromellose
- benzodiaceptine
- theno
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- -1 hydroxypropyl Chemical group 0.000 abstract 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
- 229960003943 hypromellose Drugs 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 239000001856 Ethyl cellulose Substances 0.000 abstract 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 abstract 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 abstract 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 abstract 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000004067 bulking agent Substances 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000002706 dry binder Substances 0.000 abstract 1
- 229920001249 ethyl cellulose Polymers 0.000 abstract 1
- 235000019325 ethyl cellulose Nutrition 0.000 abstract 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
El invento se refiere a una formulación oral sólida que comprende alanzapina como ingrediente activo, mezclada intimamanete con un agente de carga; aglutinante, disgregante, un aglutinante seco para proporcionar fiabilidad adecuada, y un lubricante; en la que dicha formulación oral sólida está recubierta con un polímero seleccionado entre el grupo formado por hidroxipopil hipromelosa, hidroxietil celulosa, metilhidroxietil celulosa, carboxihipromelosa de sodio, hidroxipropil celulosa, polivinilpirrolidona, copolímero del éster dimetilaminoetílico metacrilato-éster dimetilaminoetílico metilacrilato, copolímero de etilacrilato-metilmetacrilato, hipromelosa y etilcelulosa.The invention relates to a solid oral formulation comprising alanzapine as an active ingredient, intimately mixed with a bulking agent; binder, disintegrant, a dry binder to provide adequate reliability, and a lubricant; wherein said solid oral formulation is coated with a polymer selected from the group consisting of hydroxypropyl hypromellose, hydroxyethyl cellulose, methylhydroxyethyl cellulose, sodium carboxypromellose, hydroxypropyl cellulose, polyvinylpyrrolidone, dimethylaminoethyl methacrylatyl-ethyl acrylate ester copolymer methyl methacrylate, hypromellose and ethyl cellulose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP961693 ECSP961693A (en) | 1996-03-21 | 1996-03-21 | ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP961693 ECSP961693A (en) | 1996-03-21 | 1996-03-21 | ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP961693A true ECSP961693A (en) | 1997-09-22 |
Family
ID=42042425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP961693 ECSP961693A (en) | 1996-03-21 | 1996-03-21 | ORAL FORMULATION OF 2- METHYL-THENO-BENZODIACEPTINE |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP961693A (en) |
-
1996
- 1996-03-21 EC ECSP961693 patent/ECSP961693A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4700474A1 (en) | ORAL FORMULATION OF 2-METHYL-THENO-BENZODIACEPINE | |
| CL2004001182A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES A MICROPARTICLE OF SUSTAINED RELEASE THAT CONTAINS A DERIVATIVE OF 1,2 BENZAZOL; MICROPARTICLE PREPARATION PROCEDURE; USEFUL AS BRONCODILATADOR, ANTIPSICOTICOS AND IN OTHER PROBLEMS OF THE S | |
| ES8200557A1 (en) | A PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION OF SUSTAINED ASSIGNMENT OF A MEDIUM SOLID PRODUCT. | |
| MXPA02003321A (en) | Controlled release compositions comprising nimesulide. | |
| AR049055A2 (en) | A QUICKLY REMOVABLE TABLET FOR ORAL ROUTE ADMINISTRATION | |
| ES2159591T3 (en) | COMPOSITION OF CONTROLLED RELEASE. | |
| AR003908A1 (en) | CONTROLLED RELEASE TABLET | |
| DK1276470T3 (en) | Flavor-crushing coating composition | |
| TR200100931T2 (en) | New sustained release oral formulations | |
| ES2101082T3 (en) | CONTROLLED RELEASE COMPOSITIONS. | |
| AR020610A1 (en) | USE OF A TYPE C METACRYLIC ACID COPOLYMER ACCORDING TO THE US NATIONAL FORMULARY USP / NF PHARMACOPEA, AS A DEGREGATION AGENT AND THE MANUFACTURING PROCEDURE OF A TABLET WITH SUCH COPOLYMER | |
| DE69636724D1 (en) | THREE DIFFERENT POLYMER TYPE-CONTAINING FORMULATION WITH DELAYED RELEASE | |
| ATE306254T1 (en) | PREPARATIONS WITH IMPROVED CONTROLLED RELEASE | |
| ES2094781T3 (en) | PHARMACEUTICAL COMPOSITION OF MICROPARTICLES WITH CONTROLLED RELEASE AND ITS PREPARATION PROCESS. | |
| EE200100693A (en) | New dosage form | |
| AR022672A1 (en) | A PHARMACEUTICAL COMPOSITION IN THE FORM OF TABLETS OR CAPSULES THAT CONSTITUTE AN ORAL ADMINISTRATION METHOD OF A DRUG | |
| EA200001201A3 (en) | Matrix tablet for prolonged release of trimetazidine | |
| UA94917C2 (en) | Topical formulations | |
| AR021578A1 (en) | FORMULATION IN PRAVASTATIN PEARLS WITH ENTERIC COATING | |
| ES2196620T3 (en) | FORMULATION OF PROLONGED RELEASE CONTAINING VENLAFAXINE. | |
| AR021934A1 (en) | COMPOSITION OF ORAL ADMINISTRATION WITH CONTROLLED RELEASE OF AT LEAST ONE ANALGESIC | |
| HRP20010684B1 (en) | DIRECTLY STLACITIC MATRIX FOR CONTROLLED RELEASE OF A SINGLE-DAILY DOSE OF CLARITROMYCIN | |
| YU17899A (en) | Pharmaceutical microspheres of valproic acid for oral administration | |
| EA200300110A1 (en) | COMPOSITION OF ELETRIPTANE AS PARTICLES | |
| ES2126265T3 (en) | DELAYED ACTION TABLET WITH A CERTAIN CONTENT OF SODIUM DICHLOROPHENE. |